Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)

Hu,Rong; Hilakivi-Clarke,Leena; Clarke,Robert

doi:10.3892/ol.2015.2962

Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)

Authors:
- Rong Hu
- Leena Hilakivi-Clarke
- Robert Clarke
View Affiliations

Affiliations: Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C. 20057, USA
Published online on: February 12, 2015 https://doi.org/10.3892/ol.2015.2962
Pages: 1495-1501

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tamoxifen has been prescribed to millions of females for breast cancer prevention or treatment. However, tamoxifen is known to significantly enhance the risk of developing endometrial lesions, including hyperplasia, polyps, carcinomas, and sarcoma. Notably, tamoxifen‑associated endometrial cancer often has a poor clinical outcome. Understanding the molecular mechanism of tamoxifen‑induced endometrial cancer is essential for developing strategies that minimize tamoxifen's effects on the endometrium without jeopardizing its breast cancer treatment effects. However, this understanding remains limited. Tamoxifen appears to mediate its effect on endometrial cells through estrogenic and non‑genomic pathways, rather than introducing a genomic alteration as a carcinogen. Although tamoxifen functions as an agonist and promotes cell proliferation in endometrial cancer, it also displays antagonist activity towards some estrogen targets. Alterations in estrogen receptor‑α and its isoforms, as well as the membrane associated estrogen receptor G protein‑coupled receptor 30, have been observed with tamoxifen‑exposed endometrial cells, and likely mediate the effects of tamoxifen on endometrial cancer cell proliferation and invasion. In addition, gene profile studies of short‑term exposure to tamoxifen indicate that the majority of tamoxifen targets are tamoxifen‑specific. However, the tamoxifen regulated gene targets that are involved in mediating the effects of long‑term exposure to tamoxifen are not yet fully understood. Recent progress has indicated a potential role of unfolded protein response and mammalian target of rapamycin signaling in tamoxifen‑associated endometrial cancer. In the future, studies focusing on long‑term effects of tamoxifen exposure are required to understand the molecular mechanisms of tamoxifen‑associated endometrial cancer.

View Figures

View References

1	Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen. Longer Against Shorter (ATLAS) Collaborative Group: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 381:805–816. 2013. View Article : Google Scholar :
2	Jordan VC: Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst. 89:747–749. 1997. View Article : Google Scholar : PubMed/NCBI
3	Jones ME, van Leeuwen FE, Hoogendoorn WE, et al: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 14:R912012. View Article : Google Scholar : PubMed/NCBI
4	Cohen I: Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 94:256–266. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J and van Leeuwen FE: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet. 356:881–887. 2000. View Article : Google Scholar : PubMed/NCBI
6	Swerdlow AJ and Jones ME; British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 97:375–384. 2005. View Article : Google Scholar : PubMed/NCBI
7	Berlière M, Charles A, Galant C and Donnez J: Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 91:40–44. 1998. View Article : Google Scholar : PubMed/NCBI
8	Garuti G, Cellani F, Centinaio G, Sita G, Nalli G and Luerti M: Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women. Gynecol Oncol. 98:63–67. 2005. View Article : Google Scholar : PubMed/NCBI
9	López DM, Fernández YG, Sánchez AV, Alvarez MI, Reynaldo MI and Delgado RC: Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer. Menopause. 20:64–71. 2013. View Article : Google Scholar
10	Garuti G, Cellani F, Centinaio G, Sita G, Nalli G and Luerti M: Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer. Gynecol Oncol. 101:269–273. 2006. View Article : Google Scholar
11	Bland AE, Calingaert B, Secord AA, et al: Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 112:150–154. 2009. View Article : Google Scholar
12	Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. Science. 295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
13	Fong CJ, Burgoon LD, Williams KJ, Forgacs AL and Zacharewski TR: Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice. BMC Genomics. 8:1512007. View Article : Google Scholar : PubMed/NCBI
14	Zhang H, McElrath T, Tong W and Pollard JW: The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation. J Endocrinol. 184:129–140. 2005. View Article : Google Scholar : PubMed/NCBI
15	Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG and Hollema H: The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol. 55:514–519. 2002. View Article : Google Scholar : PubMed/NCBI
16	Mourits MJ, Hollema H, de Vries EG, Ten Hoor KA, Willemse PH and Van Der Zee AG: Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol. 33:341–346. 2002. View Article : Google Scholar : PubMed/NCBI
17	Vaillant F, Merino D, Lee L, et al: Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 24:120–129. 2013. View Article : Google Scholar : PubMed/NCBI
18	Acconcia F, Barnes CJ and Kumar R: Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology. 147:1203–1212. 2006. View Article : Google Scholar
19	Tsai CL, Wu HM, Lin CY, et al: Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα). PLoS One. 8:e729992013. View Article : Google Scholar
20	Taylor AH, Kalathy V and Habiba M: Estradiol and tamoxifen enhance invasion of endometrial stromal cells in a three-dimensional coculture model of adenomyosis. Fertil Steril. 101:288–293. 2014. View Article : Google Scholar
21	Cooke PS, Buchanan DL, Young P, et al: Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A. 94:6535–6540. 1997. View Article : Google Scholar : PubMed/NCBI
22	Williams GM, Iatropoulos MJ, Djordjevic MV and Kaltenberg OP: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:315–317. 1993. View Article : Google Scholar : PubMed/NCBI
23	Hard GC, Williams GM and Iatropoulos MJ: Tamoxifen and liver cancer. Lancet. 342:444–445. 1993. View Article : Google Scholar : PubMed/NCBI
24	Carthew P, Martin EA, White IN, et al: Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res. 55:544–547. 1995.PubMed/NCBI
25	Hirsimäki P, Hirsimäki Y, Nieminen L and Payne BJ: Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol. 67:49–54. 1993. View Article : Google Scholar : PubMed/NCBI
26	Vancutsem PM, Lazarus P and Williams GM: Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res. 54:3864–3867. 1994.PubMed/NCBI
27	Furr BJ and Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 25:127–205. 1984. View Article : Google Scholar : PubMed/NCBI
28	Carmichael PL, Sardar S, Crooks N, et al: Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis. 20:339–342. 1999. View Article : Google Scholar : PubMed/NCBI
29	Beland FA, Churchwell MI, Doerge DR, et al: Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J Natl Cancer Inst. 96:1099–1104. 2004. View Article : Google Scholar : PubMed/NCBI
30	Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP and Pearl ML: Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis. 21:1461–1467. 2000. View Article : Google Scholar : PubMed/NCBI
31	Shibutani S, Suzuki N, Terashima I, Sugarman SM, Grollman AP and Pearl ML: Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol. 12:646–653. 1999. View Article : Google Scholar : PubMed/NCBI
32	Andersson H, Helmestam M, Zebrowska A, Olovsson M and Brittebo E: Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 38:200–207. 2010. View Article : Google Scholar
33	Fles R, Hoogendoorn WE, Platteel I, et al: Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer. 49:699–710. 2010. View Article : Google Scholar : PubMed/NCBI
34	Yeramian A, Moreno-Bueno G, Dolcet X, et al: Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 32:403–413. 2013. View Article : Google Scholar
35	Lagarda H, Catasus L, Arguelles R, Matias-Guiu X and Prat J: K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol. 193:193–199. 2001. View Article : Google Scholar : PubMed/NCBI
36	Sun H, Enomoto T, Shroyer KR, et al: Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagn Mol Pathol. 11:204–211. 2002. View Article : Google Scholar : PubMed/NCBI
37	Prasad M, Wang H, Douglas W, Barakat RR and Ellenson LH: Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol. 96:25–31. 2005. View Article : Google Scholar
38	Turbiner J, Moreno-Bueno G, Dahiya S, et al: Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol. 21:925–936. 2008. View Article : Google Scholar : PubMed/NCBI
39	Yasue A, Hasegawa K and Udagawa Y: Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity. Hum Cell. 24:65–73. 2011. View Article : Google Scholar : PubMed/NCBI
40	Holtz D, Ramondetta LM, Burke TW, Palazzo JP, Dunton CJ, Atkinson EN and Broaddus RR: PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 22:2945–2948. 2002.
41	Wallén M, Tomás E, Visakorpi T, Holli K and Mäenpää J: Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother Pharmacol. 55:343–346. 2005. View Article : Google Scholar
42	Hachisuga T, Miyakawa T, Tsujioka H, Horiuchi S, Emoto M and Kawarabayashi T: K-ras mutation in tamoxifen-related endometrial polyps. Cancer. 98:1890–1897. 2003. View Article : Google Scholar : PubMed/NCBI
43	Hachisuga T, Tsujioka H, Horiuchi S, Udou T, Emoto M and Kawarabayashi T: K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br J Cancer. 92:1098–1103. 2005. View Article : Google Scholar : PubMed/NCBI
44	Miranda SP, Traiman P, Cândido EB, et al: Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen. Int J Gynecol Cancer. 20:1525–1530. 2010.PubMed/NCBI
45	Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:753–758. 1997. View Article : Google Scholar : PubMed/NCBI
46	McDonnell DP: The molecular determinants of estrogen receptor pharmacology. Maturitas. 48(Suppl 1): S7–12. 2004. View Article : Google Scholar : PubMed/NCBI
47	Shah YM and Rowan BG: The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol. 19:732–748. 2005. View Article : Google Scholar
48	Elkas J, Armstrong A, Pohl J, Cuttitta F, Martínez A and Gray K: Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen. Obstet Gynecol. 95:697–703. 2000. View Article : Google Scholar : PubMed/NCBI
49	Mehasseb MK, Bell SC and Habiba MA: The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction. 138:341–350. 2009. View Article : Google Scholar : PubMed/NCBI
50	Lin SL, Yan LY, Zhang XT, et al: ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One. 5:e90132010. View Article : Google Scholar : PubMed/NCBI
51	Filardo EJ, Quinn JA, Frackelton AR Jr and Bland KI: Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 16:70–84. 2002. View Article : Google Scholar : PubMed/NCBI
52	Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE and Prossnitz ER: GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 196:3862007. View Article : Google Scholar : PubMed/NCBI
53	Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S and Maggiolini M: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 20:631–646. 2006. View Article : Google Scholar
54	Ignatov T, Eggemann H, Semczuk A, et al: Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am J Obstet Gynecol. 203:5952010. View Article : Google Scholar : PubMed/NCBI
55	Tamm-Rosenstein K, Simm J, Suhorutshenko M, Salumets A and Metsis M: Changes in the transcriptome of the human endometrial Ishikawa cancer cell line induced by estrogen, progesterone, tamoxifen, and mifepristone (RU486) as detected by RNA-sequencing. PLoS One. 8:e689072013. View Article : Google Scholar : PubMed/NCBI
56	Pole JC, Gold LI, Orton T, Huby R and Carmichael PL: Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen. Toxicology. 206:91–109. 2005. View Article : Google Scholar
57	Gielen SC, Santegoets LA, Hanifi-Moghaddam P, Burger CW and Blok LJ: Signaling by estrogens and tamoxifen in the human endometrium. J Steroid Biochem Mol Biol. 109:219–223. 2008. View Article : Google Scholar : PubMed/NCBI
58	Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR and Boyd J: Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 92:719–725. 2004. View Article : Google Scholar : PubMed/NCBI
59	Gielen SC, Kühne LC, Ewing PC, Blok LJ and Burger CW: Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer. 12:1037–1049. 2005. View Article : Google Scholar : PubMed/NCBI
60	Clarke R, Cook KL, Hu R, et al: Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 72:1321–1331. 2012.PubMed/NCBI
61	Cook KL, Shajahan AN, Wärri A, Jin L, Hilakivi-Clarke LA and Clarke R: Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res. 72:3337–3349. 2012. View Article : Google Scholar : PubMed/NCBI
62	Gomez BP, Riggins RB, Shajahan AN, et al: Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 21:4013–4027. 2007. View Article : Google Scholar : PubMed/NCBI
63	Tergas AI, Buell-Gutbrod R, Gwin K, et al: Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 127:316–320. 2012. View Article : Google Scholar : PubMed/NCBI
64	Erdemoglu E, Güney M, Take G, Giray SG and Mungan T: RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia. Int J Gynecol Cancer. 19:375–379. 2009. View Article : Google Scholar : PubMed/NCBI